Items where authors include "Faust, SN"

Article

Hardt, K, Vandebosch, A, Sadoff, J et al. (285 more authors) (2022) Efficacy, safety, and immunogenicity of a booster regimen of Ad26.COV2.S vaccine against COVID-19 (ENSEMBLE2) : results of a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet Infectious Diseases, 22 (12). pp. 1703-1715. ISSN 1473-3099

Abani, O, Abbas, A, Abbas, F et al. (6300 more authors) (2022) Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. The Lancet, 399 (10325). pp. 665-676. ISSN 0140-6736

Swanson, PA, Padilla, M, Hoyland, W et al. (67 more authors) (2021) AZD1222/ChAdOx1 nCoV-19 vaccination induces a polyfunctional spike protein-specific Th1 response with a diverse TCR repertoire. Science Translational Medicine, 13 (620). eabj7211. ISSN 1946-6234

Flaxman, A, Marchevsky, NG, Jenkin, D et al. (184 more authors) (2021) Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002). The Lancet, 398 (10304). pp. 981-990. ISSN 0140-6736

Swanson, PA, Padilla, M, Hoyland, W et al. (63 more authors) (2021) T-cell mediated immunity after AZD1222 vaccination : a polyfunctional spike-specific Th1 response with a diverse TCR repertoire. medRxiv. (Submitted)

Abani, O, Abbas, A, Abbas, F et al. (4809 more authors) (2021) Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial. The Lancet, 397 (10289). pp. 2049-2059. ISSN 0140-6736

Abani, O orcid.org/0000-0003-2209-9956, Abbas, A, Abbas, F et al. (6346 more authors) (2021) Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. The Lancet, 397 (10285). pp. 1637-1645. ISSN 0140-6736

Emary, KRW, Golubchik, T, Aley, PK et al. (64 more authors) (2021) Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7) : an exploratory analysis of a randomised controlled trial. The Lancet, 397 (10282). pp. 1351-1362. ISSN 0140-6736

Voysey, M, Costa Clemens, SA, Madhi, SA et al. (763 more authors) (2021) Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials. The Lancet, 397 (10277). pp. 881-891. ISSN 0140-6736

Voysey, M, Clemens, SAC, Madhi, SA et al. (80 more authors) (2020) Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. The Lancet, 397 (10269). pp. 99-111. ISSN 0140-6736

Coulter, TI, Chandra, A, Bacon, CM et al. (55 more authors) (2017) Clinical spectrum and features of activated phosphoinositide 3-kinase δ syndrome: A large patient cohort study. Journal of Allergy and Clinical Immunology, 139 (2). pp. 597-606. ISSN 0091-6749